Soc. Generale Knock-Out MRK/ DE000CL7XF23 /
2024-05-15 8:37:49 PM | Chg.+0.650 | Bid8:48:12 PM | Ask8:48:12 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
5.430EUR | +13.60% | 5.420 Bid Size: 3,000 |
5.490 Ask Size: 3,000 |
MERCK KGAA O.N. | 111.2244 - | 2078-12-31 | Call |
GlobeNewswire
2:30 PM
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire
2:05 PM
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
2:00 PM
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA